EASL International Recognition Award Recipient 2019； Full Professor of Division of Clinical Gastroenterology and Hepatology, Hospital das Clínicas HCFMUSP, Department of Gastroenterology, University of São Paulo School of Medicine, Sao Paulo, Brazil.
The systemic treatment of advanced hepatocellular carcinoma has rapidly evolved in the last years. Until the demonstration of the survival benefit of sorafenib in 2007, no effective treatments were available. The positive results with sorafenib represented a major breakthrough and triggered interest in the evaluation of new agents. After multiple failures, recent agents have proven benefit, significantly extending the survival of advanced hepatocellular carcinoma. This hopeful scenario has been crowned by the recently published results of the IMBRAVE-150 trial. This trial proved superiority of atezolizumab plus bevacizumab over sorafenib.
Currently, several ongoing trials are evaluating the activity of dual immunotherapy combinations or combinations of tyrosine kinase inhibitors plus immunotherapy. Some of these results are planned to be announced in the following years.
Within this context, it is possible to state that advanced HCC will move from a rapidly lethal malignancy to a chronic condition. This will require critical insight and deep knowledge of the available data.
We invite you to contribute to the upcoming special issue about "Systemic Treatment for Hepatocellular Carcinoma" and hope you will be able to join us in this journey.
The following topics are what we would like to to discuss in this special issue:
1. Combination immunotherapy + TKI
2. Combination dual immunotherapy
3. Potential biomarkers of response to systemic treatment
4. Mechanisms of resistance in HCC
5. Sequencing strategies
6. Tyrosine kinase inhibitors
7. Role of immunotherapy
8. Combination of systemic treatment and local modalities
9. (Neo) adjuvant systemic treatment
10. Radiological response assessment in patients under systemic treatment